🔥🐔 BizChicken 🐔🔥

Companies Similar to Ligand Pharmaceuticals Incorporated

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

EVOMELA

CASI Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products focusing on markets in China, the United States, and internationally. Major products include EVOMELA and a pipeline with several investigational products targeting various cancers.

Tags: CAR-T, biopharmaceutical, cancer treatment, clinical trials, multiple myeloma, pharmaceutical, therapeutics

Symbol: CASI

Recent Price: $2.93

Industry: Biotechnology

CEO: Dr. Wei-Wu He Ph.D.

Sector: Healthcare

Employees: 176

Address: 9620 Medical Center Drive, Rockville, MD 20850

Phone: 240 864 2600

Last updated: 2024-12-31

Amgen Inc.

Amgen Inc. logo
Market Cap: Highest
Employees: Highest

Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, Repatha, Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide, focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Tags: biotechnology, bone health, cardiovascular, healthcare, inflammation, neuroscience, oncology, pharmaceuticals, therapeutics

Symbol: AMGN

Recent Price: $259.30

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Bradway

Sector: Healthcare

Employees: 26700

Address: One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Phone: 805 447 1000

Leadership

  • Robert A. Bradway, Chairman and Chief Executive Officer
  • James Bradner, Executive Vice President, Research and Development, and Chief Scientific Officer
  • Sean Bruich, Senior Vice President Artificial Intelligence and Data
  • Paul Burton, Senior Vice President and Chief Medical Officer
  • Raymond Deshaies, Senior Vice President, Global Research
  • Jackie Elbonne, Senior Vice President, Quality and Chief Quality Officer
  • Murdo Gordon, Executive Vice President, Global Commercial Operations
  • Jonathan Graham, Executive Vice President and General Counsel and Secretary
  • Peter Griffith, Executive Vice President and Chief Financial Officer
  • Nancy Grygiel, Senior Vice President, Worldwide Compliance & Business Ethics and Chief Compliance Officer
  • Narimon Honarpour, Senior Vice President, Global Development
  • Vikram Karnani, Executive Vice President, and President, Global Commercial Operations and Medical Affairs (Rare Disease)
  • My Linh Kha, Senior Vice President and General Manager, Japan Asia-Pacific
  • Rachna Khosla, Senior Vice President, Business Development
  • Gilles Marrache, Senior Vice President, Regional General Manager
  • Derek Miller, Senior Vice President, Human Resources
  • Jerry Murry, Senior Vice President, Process Development
  • Kave Niksefat, Senior Vice President, Global Marketing and Access
  • Arleen Paulino, Senior Vice President, Manufacturing
  • Annalisa Pizzarello, Senior Vice President, Results Delivery Office
  • Greg Portner, Senior Vice President, Global Government Affairs and Policy
  • Anton Rabushka, Senior Vice President, Finance
  • Emily Razaqi, Senior Vice President, Obesity and Related Conditions
  • David M. Reese, Executive Vice President and Chief Technology Officer
  • Esteban Santos, Executive Vice President, Operations
  • Darryl Sleep, Senior Vice President, Global Medical
  • Jean-Charles Soria, Senior Vice President, Research and Development
  • Susan Sweeney, Executive Vice President, Obesity and Related Conditions
  • Mark J. Taisey, Senior Vice President, Global Regulatory Affairs and Strategy
  • Susie Tappouni, Head of Corporate Affairs
  • Ian Thompson, Senior Vice President, U.S. Business Operations
  • Brenda Torres, Senior Vice President, Global Supply Chain
  • Alper Üreten, Vice President, Commercialization and Program Management
  • Wanda M. Austin, Retired President and Chief Executive Officer, The Aerospace Corporation
  • Michael V. Drake, President, University of California
  • Brian J. Druker, Physician-Scientist and Professor of Medicine, Oregon Health & Science University (OHSU), Director of the OHSU Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, and Associate Dean for Oncology, OHSU School of Medicine
  • Robert A. Eckert, Lead Independent Director, Chairman Emeritus, Mattel, Inc.
  • Greg C. Garland, Former Executive Chairman and Former Chairman and Chief Executive Officer, Phillips 66
  • Charles M. Holley, Jr., Former Executive Vice President and Chief Financial Officer of Wal-Mart Stores, Inc.
  • S. Omar Ishrak, Former Executive Chairman and Chairman of the Board of Directors, Medtronic plc
  • Tyler Jacks, David H. Koch Professor of Biology, Massachusetts Institute of Technology and Founding Director of the David H. Koch Institute for Integrative Cancer Research
  • Mary E. Klotman, Executive Vice President for Health Affairs of Duke University, Dean of the Duke University School of Medicine, and Chief Academic Officer of Duke Health
  • Ellen J. Kullman, Executive Chair of the Board and Former President and Chief Executive Officer of Carbon, Inc.
  • Amy E. Miles, Former Chair of the Board and Chief Executive Officer, Regal Entertainment Group, Inc.

Last updated: 2024-12-31

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. logo
Market Cap: Low
Employees: Low

LYL797, LYL845, NY-ESO-1

Lyell Immunopharma, Inc. is a biopharmaceutical company developing T cell therapies focused on treating patients with solid tumors using advanced genetic and epigenetic reprogramming technologies.

Tags: T cell therapy, biotechnology, cancer treatment, epigenetic reprogramming, genetic reprogramming, solid tumors

Symbol: LYEL

Recent Price: $0.62

Industry: Biotechnology

CEO: Dr. Lynn Seely M.D., Ph.D.

Sector: Healthcare

Employees: 224

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650 695 0677

Leadership

  • Lynn Seely, M.D., President & Chief Executive Officer
  • Stephen Hill, Chief Operating Officer
  • Matthew Lang, J.D., Chief Business Officer
  • Gary Lee, Ph.D., Chief Scientific Officer
  • Charles Newton, Chief Financial Officer
  • Ellen Rose, Senior Vice President, Investor Relations and Communications
  • Bryan Selby, Senior Vice President, Clinical Development Operations
  • Ann Tomlin, Senior Vice President, Human Resources
  • Rick Klausner, M.D., Founder & Board Chair
  • Crystal Mackall, M.D., Founder
  • Stan Riddell, M.D., Founder
  • Hans Bishop, Director
  • Otis Brawley, M.D., Director
  • Catherine Friedman, Director
  • Elizabeth Nabel, M.D., Director
  • Robert Nelsen, Director
  • William Rieflin, Director

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ZYESAMI, NRX-100, NRX-101

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Tags: CNS disorders, COVID-19 treatment, bipolar depression, clinical-stage pharmaceutical, pulmonary diseases, suicidal behavior

Symbol: NRXP

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Sector: Healthcare

Employees: 2

Address: 1201 Orange Street, Wilmington, DE 19801

Phone: 484 254 6134

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

ZN-c3, ZN-c5

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for treating various cancers. Its leading product candidates include ZN-c3 and ZN-c5, which are in various phases of clinical trials targeting specific cancer types.

Tags: biopharmaceutical, cancer treatment, clinical trials, small molecule therapeutics

Symbol: ZNTL

Recent Price: $2.92

Industry: Biotechnology

CEO: Dr. Kimberly Lynn Blackwell M.D.

Sector: Healthcare

Employees: 124

Address: 1359 Broadway, New York, NY 10018

Phone: 212 433 3791

Last updated: 2024-12-31

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Medium

AMX0035

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.

Tags: ALS, AMX0035, biopharmaceutical, neurodegenerative diseases, therapeutics

Symbol: AMLX

Recent Price: $3.84

Industry: Biotechnology

CEO: Mr. Joshua B. Cohen

Sector: Healthcare

Employees: 384

Address: 43 Thorndike Street, Cambridge, MA 02141

Phone: 617 682 0917

Leadership

  • Linda A. Arsenault, Chief Human Resources Officer
  • Camille L. Bedrosian, MD, Chief Medical Officer
  • Josh Cohen, Co-CEO & Co-Founder
  • James M. Frates, Chief Financial Officer
  • Tom Holmes, Chief Technical Operations Officer
  • Justin Klee, Co-CEO & Co-Founder
  • Gina M. Mazzariello, Chief Legal Officer & General Counsel
  • Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
  • Wally Gilbert, Special Advisor
  • Kari Firestone, Director
  • Paul Fonteyne, Director
  • George Milne, Chairman
  • Daphne Quimi, Director
  • Bernhardt G. Zeiher, MD, FACP, FCCP, Director

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

Tavalisse

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

Tags: biotechnology, cancer, drug development, hematologic disorders, immune diseases

Symbol: RIGL

Recent Price: $16.47

Industry: Biotechnology

CEO: Mr. Raul R. Rodriguez

Sector: Healthcare

Employees: 147

Address: 1180 Veterans Boulevard, South San Francisco, CA 94080

Phone: 650 624 1100

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31